Eisai To Distribute Ajinomoto Drugs In 11 Asian Nations Outside Japan
This article was originally published in PharmAsia News
Japan's Ajinomoto has arranged for Esai to distribute its Livact Granules (amino acid) hepatic liver cirrhosis drug in Asian countries outside Japan. The two companies also are discussing having Esai get approval for and distribute other Ajinomoto digestive system drugs abroad as part of the company's goal of a 20 percent sales increase. The Livact agreement calls for Esai to target nine countries: Cambodia, China, India, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Sri Lanka, Thailand and Vietnam. (Click here for more - a subscription may be required
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.